fingolimod + siponimod

Fingolimod + siponimod is a hypothetical combination of two oral small molecule sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis (MS). Both drugs act by modulating S1P receptors on lymphocytes and central nervous system cells to reduce neuroinflammation and slow disease progression. Fingolimod is a non-selective S1P receptor modulator targeting S1P subtypes 1, 3, 4, and 5; it prevents egress of lymphocytes from lymph nodes and has additional direct effects within the CNS. Siponimod is more selective for S1P subtypes 1 and 5; this selectivity reduces certain side effects associated with broader S1P modulation. Both drugs decrease peripheral blood lymphocyte counts but differ in pharmacokinetics—fingolimod has a longer half-life than siponimod—and in their clinical indications. Fingolimod is primarily approved for relapsing forms of MS including relapsing-remitting MS (RRMS), while siponimod is specifically approved for active secondary progressive MS (SPMS)[3][4][5][7]. There are no known marketed or investigational products combining both agents into a single formulation.